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Retinoic acid (RA) induces partial differentiation f neuroblastoma (NB) cells in vitro. In the human NB line, SH-SY5Y 
(a neuroblastic subelone of SK-N-SH), RA was previously shown to enhance the stimulatory (PGE1) and inhibitory 
(opioid) regulation of adenylyl cyclas¢. Since these cells are also sensitive to cAMP stimulation by vasoactive intestinal 
peptide (VIP), we have tested the effects of RA on VIP receptor expression and function. Pretreatment of SH-SY5Y cells 
with 10/~M RA over 6 days dramatically increased VIP receptor number from ~ 3 000 to ~ 70 000 sites per cell and 
enhanced threefold the cAMP accumulation after external VIP addition, while VIP immunoreactive content in the cells 
increased 2-3-fold. In the light of the recently proposed autocrine function of VIP in this cell lineage, the strong enhance- 
ment of the VIP system may contribute to the differentiation effects of RA. 
Vasoactive intestinal peptide; Vasoactive intestinal peptide receptor; cyclic AMP stimulation; Retinoic acid; 
Neuroblastoma differentiation; (SH-SY5Y human neuroblastoma cell) 
1. INTRODUCTION 
Neuroblastoma (NB) is the most common ex- 
tracranial solid tumor in early childhood. While it 
occasionally develops into a benign differentiated 
ganglioneuroma, prognosis is generally poor and 
treatment limited. Differentiation of immature NB 
cells to a more benign and less invasive phenotype 
represents one promising avenue of therapy, and 
retinoic acid (RA) has shown some promise on the 
basis of in vitro studies, particularly in combina- 
tion with other agents [I]. We have recently shown 
that RA greatly enhances the regulation of adenylyl 
cyclase by prostaglandins [2]and opioids [3], in the 
neuroblastic NB line SH-SY5Y, which is a subclone 
of the SK-N-SH cell lineage [4]. Further, we have 
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recently demonstrated that the various cell types 
expressed by SK-N-SH contain VIP precursor 
mRNA, secrete VIP immunoreactivity, express 
VIP receptors, and respond to VIP with elevated 
cAMP levels [5]. Thus, VIP may serve an autocrine 
function in SK-N-SH and affect he differentiation 
process, since cAMP (as dibuturyl cAMP) induces 
partial neuronal differentiation [6]. We have 
therefore tested the effect of RA on VIP-receptor 
binding and the VIP-cAMP response in SH-SY5Y 
cells. 
2. MATERIALS AND METHODS 
2.1. Cell culture 
The neuroblastic subclone of SK-N-SH, i.e., SH-SY5Y, was 
established by Roses et al. [4]. SH-SY5Y ceils, in their 40th to 
50th passage after subcloning, were cultured in DMEM (from 
Whittacker M.A. Bioproducts) as described previously [3,5]. 
The cells were treated for 6 days with either 10/zM RA dissolved 
in aqueous ethanol (unless indicated otherwise) or with equal 
ethanol concentrations as a control. Medium was replaced every 
2 days. Total protein was measured with the Biorad ® reagent 
and bovine serum albumin as a standard. 106 SH-SY5Y cells 
contain 100-150/~g protein. 
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2.2. VIP radioimmuno assay 
SH-SY5Y cells were plated at 1 x 105 cells/16 mm well. 
Treatment with RA was begun on day 2, and cells were 
harvested on day 8 in 0.1 N HCI. VIP content of the cells was 
measured by RIA as described [7], using N12 VIP antiserum 
(kindly provided by Dr G. Nilaver, Columbia University College 
of Physicians and Surgeons). 
2.3. VIP receptor assay 
SH-SY5Y cells were plated in 24 well (16 mm) culture plates 
at a density of 1 × 10 s cells/well and treated with RA as above. 
Binding was performed in the culture wells, on the intact cells, 
as previously described [8]. Cells were first preincubated for 30 
rain at 37°C in binding medium, and then incubated in the bin- 
ding medium with 30 pM [3-[1251]iodo Tyr t°] VIP (2000 
Ci/mmol, from Amersham) with or without unlabeled VIP, for 
3 h at 4°C. The excess 12SI-VIP was then removed by three 
washes of binding medium (4°C), and the ceils were harvested 
with 0.5 M NaOH for assay of 125I content. 
Table 1 
Effect of 6-day pretreatment of SH-SY5Y cells with RA on VIP 
immunoreactivity 
Pretreatment VIP equivalent in cell 
extract ng/mg protein 
(mean ± SE, n = 3) 
Ethanol control for 10 -6 M RA 0.6 ± 0.006 
Ethanol control for 10 -5 M RA 0.7 ± 0.01 
RA, 10-gM 0.6 ± 0.003 
RA, 10-SM 0.6 ± 0.006 
RA, 10-7M 0.6 + 0.003 
RA, 10-6M 1.1 + 0.003 
RA, 10-SM 1.5 _+ 0.3 
Ethanol controls matched ethanol concentrations in the 10 -5 
and 10 -6 M RA solutions, but were insignificant at higher RA 
dilutions 
2.4. cAMP assay 
SH-SYSY cells were seeded at 2 x 105 cells per 16 mm well. 
After 6 days, culture medium was removed, ceils were washed 
once with 1 ml serum-free medium and equilibrated at 37°C for 
15 min in the same medium containing 0.5 mM 
3-isobutyl-l-methylxanthine (IBMX, from Sigma Co.). cAMP 
was measured by RIA as described [2]. 
3. RESULTS 
The  cel lu lar  content  o f  V IP  immuno- react ive  
mater ia l  was determined  a f ter  6 -day  pret reatments  
w i th  or  w i thout  10/~M RA.  The  resu l ts  in tab le  1 in- 
d icate  that  RA at  or  above  1/~m enhances  V IP  con-  
tent  2 -3 - fo ld .  A much larger  RA ef fect ,  however ,  
was  observed  on  V IP  receptor  express ion  ( f ig . l ) .  
Computer i zed  f i t t ing o f  the  125I-VIP d i sp lacement  
curves  to  a one-s i te  b ind ing  mode l  [2] gave Kd 
va lues  o f  - -4  nM wi thout ,  and  9 nM wi th ,  RA  
t reatment ,  whi le  receptor  site number  per  cell in-  
c reased  dramat ica l ly  f rom -3500 to -70  000. 
In  para l le l  w i th  the  increased  V IP  receptor  
number ,  there  was a 2 -3 - fo ld  increase  in the  abi l i ty  
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Fig. 1. Competitive displacement curve (A) and Scatchard plot of ~25I-VIP binding by unlabeled V1P in SH-SY5Y cells. Specific binding 
to control cells (560000 cells per test; open triangles) or RA-treated cells (370000 cells per test; open squares) was determined as the 
difference between total binding and binding in the presence of excess unlabeled VIP (1000 riM). Data are the mean of one experiment 
(mean ± SE = 5070, n = 3). The solid lines represent the fit of data to a single site binding model with a Hill coefficient n = 1 yielding 
the following binding parameters (values of a repeat experiment in parentheses): Kd -- 4.3 nM (3.5 nM) with - 4200 (2700) recep- 
tors/cell in untreated ceils (open squares) and Kd -- 9.1 nM (8.7 nM) with - 75 000 (65 000) receptors/cell in retinoic acid-treated cells 
(B) (solid diamonds). 
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Fig.2. Dose-response curves for VIP-stimulated intracellular cAMP levels with and without 10/~M RA pretreatment. The solid line 
represents a computer fit to the equation given in the legend of table 2 (expt. 1). Error bars represent the range of duplicate values. 
of externally added VIP to maximally stimulate the 
accumulation of cellular cAMP levels (fig.2 and 
table 2). Maximum stimulation (Ei) was 1400 pmol 
cAMP/mg protein in the control, and 3900 pmol 
cAMP/mg protein with 10/zM RA pretreatment. 
However, the ECso value of VIP had shifted from 
- 10 nM to -70 nM. Measured basal cAMP levels 
increased from 31 to 71 pmol cAMP/mg protein 
with 10/~M RA pretreatment (table 2). The slope 
factors of the dose response curves (n, table 2) were 
generally close to 1; in each case, n = 1.0 was within 
the 95o7o confidence limits of the parameter 
estimates. 
4. DISCUSSION 
Our study shows that RA causes a striking in- 
crease of VIP receptor expression i the human NB 
cell line SH-SYSY, and in parallel enhanced max- 
imal stimulation of adenylyl cyclase by VIP. These 
results substantiate earlier reports that RA up- 
regulates both positive and negative control of 
adenylyl cyclase, e.g., by prostaglandin [2] and 
opioids [3] in SH-SY5Y cells, and by calcitonin [9] 
and parathyroid hormone [10] in F9 embryonal 
carcinoma cells. In each case, enhanced regulation 
of adenylyl cyclase was associated with an in- 
creased number of receptor sites per cell, although 
these increases were much less than the VIP recep- 
tor enhancement reported here. 
The large increase in VIP receptors caused by 
RA is disproportionally greater than the enhance- 
ment of cAMP accumulation by exogenous VIP. 
Further, the VIP dose-response curve (fig.2) is 
significantly shifted to the right by seven-fold, 
although higher maximal cAMP levels were ob- 
tained. These results uggest the possibility that in- 
creased endogenous activity of VIP in the cell 
cultures, triggered by RA, may have caused some 
desensitization f the VIP response. Indeed the/i'd 
for VIP receptor binding was also shifted to higher 
values by RA pretreatment (from 4 nM to 9 nM), 
assuming a single binding population. The Scat- 
chard plot in fig. 1B shows some deviation from a 
straight line, which suggests possible heterogeneity 
of the binding sites. Further work is needed to 
clarify the reasons for the apparent shift in the 
ECso of VIP after RA treatment. 
The basal cAMP level was significantly elevated 
by RA, and we have shown in earlier experiments 
[5] that conditioned medium from SK-N-SH 
cultures containing VIP immunoreactive material 
stimulates adenylyl cyclase. Further, RA failed to 
cause major changes in Gs-protein content and 
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Table 2 
Parameter estimates for the VIP-cAMP dose response curves, fitted to the 
logistic relationship En = Eo + (Ei-Eo)/[l + (ECso/D)n], where En, Eo and 
Ei are actual, initial (zero VIP) and maximal cAMP levels, D is the VIP concen- 
tration (in nM), ECho the VIP concentration causing half-maximal effect, and 
the exponential, n, is a slope factor (equivalent to the Hill coefficient) 
Control RA pretreatment 
Expt. 1 Expt. 2 Expt. l Expt. 2 
Eo (pmol cAMP/ 
mg protein) a 
Ei (pmol cAMP/ 
mg protein) 
ECso (nM) 
8.8 41 68 89 
1471 1359 4022 3793 
(1255-1718) (1137-1643) (3706-4371) (3184-4527) 
8.8 11 77 70 
(4.6-19) (5.2-30) (58-107) (43-136) 
0.83 0.84 0.92 1.0 
a Estimates of E0 are extrapolated values ubject o a large error, depending on 
the shape of the dose-response curve. The measured Eo values (no VIP added) 
were 31 pmol cAMP/rag protein (range 25-38, n=4) for the control, and 71 
pmol cAMP/rag protein (range 69-75, n = 4) for RA pretreated cells. A similar 
increase by RA pretreatment has been observed previously [2]. 
Two independent experiments with full dose-response curves were performed. 
(The actual data of expt. 1 are shown in fig.2.) The numbers in parentheses 
represent the 95% confidence limits of the parameter estimates. Since the 
ranges of the Ei and ECso estimates did not overlap with and without RA 
pretreatment, differences are significant (P<0.05) 
adenyly l  cyclase act iv i ty in SH-SY5Y  cells [2]. 
These results taken together  document  that  RA  
enhances  electively the V IP  messenger  system, in- 
c lud ing a dramat ic  increase o f  V IP  receptor  expres- 
sion. 
Because the various cell types of the SK-N-SH 
cell lineage produce VIP, express VIP receptors 
and respond to VIP by increasing cAMP levels, we 
have recently postulated an autocrine or paracrine 
role of VIP [5]. The finding here that RA enhances 
the VIP messenger system in the neuroblastic 
subclone SH-SY5Y suggests that RA effects on cell 
morphology and neuronal differentiation can be 
modulated by VIP. While the exact role of VIP re- 
mains unclear, some NB tumors secrete large 
amounts of VIP in vivo [11], leading to diarrhea in 
these patients. It is therefore possible that the 
regulation of the VIP system could represent an im- 
portant factor in NB growth and differentiation. 
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